AstraZeneca's Evusheld (AZD7442) Receives the US FDA's EUA for Pre-Exposure Prophylaxis of COVID-19
Shots:
- The US FDA has issued a EUA for Evusheld to treat pre-exposure prophylaxis of COVID-19 in adults & adolescents aged ≥12yrs. with no adequate immune response to COVID-19 vaccination & whom COVID-19 vaccination is not recommended. The 1st dose is expected to be available shortly
- In P-III (PROVENT) trial, 77% reduction in primary analysis & 83% at a median of 6mos. over PBO & showed robust efficacy & long-term protection with 1 dose in a high-risk population. The EUA is based on the P-III (STORM CHASER) & P-I (Evusheld) trial
- Evusheld is a combination of 2 LAABs i.e., tixagevimab & cilgavimab which was derived from B-cells donated by convalescent patients after a SARS-CoV-2 virus
/ article | Ref: AstraZeneca | Image: Al Jazeera
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com